相关临床试验
70
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1964
进行中（未招募）
2
2.9%
已完成
51
72.9%
招募中
8
11.4%
Unknown
7
10.0%
撤回
2
2.9%
暂无批准数据
- Rose Hill Life Sciences appointed Bryan Smith, a nearly 20-year Deciphera Pharmaceuticals veteran, as Scientific Advisor to guide its preclinical and clinical psilocybin programs. - Smith will shape scientific strategy, direct translational research and biomarker work, and support regulatory and IND/NDA documentation across the company's pipeline. - The appointment comes days after Jama Pitman, a former Deciphera chief development officer, was named CEO of the clinical-stage psychedelic therapeutics company. - Rose Hill's four programs target stroke recovery, depression, autism spectrum disorder and PTSD, with its flagship psilocybin-for-stroke-recovery program in Phase 1 with Johns Hopkins.
- Researchers at the University of Guelph are developing Canada's first bird flu vaccine using mRNA technology, targeting low pathogenic avian influenza in commercial poultry. - The mRNA platform offers high adaptability for rapidly mutating viruses, allowing researchers to make adjustments for new strains without starting from scratch. - The vaccine is being optimized for nasal administration to facilitate mass vaccination of poultry flocks, with preliminary results showing positive outcomes. - The earliest version of the vaccine could become available within a few months, with the ultimate goal of controlling virus spread within chicken populations and preventing transmission to humans.
